FTC vs FDA in Telehealth Marketing: What Each Agency Actually Regulates
Telehealth marketing can involve several regulatory frameworks at once. The FTC and FDA are two of the most important, but their roles are not interchangeable and the boundary depends on the product, claim, and context.
The practical goal is not to memorize agency acronyms. It is to know which claims need which type of review before they go live.
1. The FTC Focuses on Deceptive or Unfair Advertising Practices
The FTC's Health Products Compliance Guidance explains that health advertising must be truthful, not misleading, and supported by appropriate substantiation before the claim is made.
The agency evaluates both express and implied claims and looks at the advertisement's overall net impression.
This can include:
- website copy
- paid ads
- social content
- testimonials
- endorsements
- influencer content
- charts and images
- landing pages and sales funnels
For a deeper framework, see FTC Health Claim Rules.
2. FDA Authority Depends on the Regulated Product and Communication
FDA regulates medical products under statutes and regulations that differ by product category. Medical devices, prescription drugs, biologics, and certain software functions can have different requirements.
For a telehealth company, FDA questions often arise when the business:
- markets a medical device
- integrates a regulated diagnostic or device
- promotes prescription drugs
- markets software that may meet the definition of a medical device
- uses FDA status as part of the sales message
Not every telehealth service or software feature is FDA regulated.
3. FDA Status Words Are Not Interchangeable
“Registered,” “listed,” “cleared,” “approved,” and “authorized” can describe very different regulatory situations.
For medical devices:
- registration and listing are administrative requirements and do not mean FDA approved or cleared a device
- 510(k) clearance generally reflects a substantial-equivalence determination for the device's intended use
- De Novo is a classification pathway for certain novel device types without a legally marketed predicate
- PMA is FDA's most stringent device marketing application and is associated with many Class III devices
See FDA Medical Device Marketing Rules.
4. One Claim Can Raise Both FTC and FDA Questions
Suppose a telehealth company markets a regulated device using a strong outcome claim.
The company may need to ask:
- Does the claim accurately describe the product's FDA status and intended use?
- Is the objective health claim adequately substantiated?
- Does the overall advertisement create a broader implied claim?
- Are important limitations clear?
The right review is claim-specific, not simply “FTC or FDA.”
5. Testimonials Do Not Create a Workaround
A testimonial can communicate an objective claim. If a patient or influencer describes an outcome that the advertiser could not substantiate directly, putting it in quotation marks does not remove the risk.
The FTC's Endorsement Guides also address material connections between endorsers and advertisers.
6. Build a Claims Matrix
For each meaningful commercial claim, document:
- exact wording
- express takeaway
- implied takeaway
- product or service involved
- supporting evidence
- FDA status or labeling considerations where applicable
- qualifications
- approved channels
- reviewer and review date
This gives marketing a usable operating system rather than a vague instruction to “be compliant.”
7. Review the Entire Funnel
A compliant ad can link to a landing page that creates a broader claim. A compliant landing page can be undermined by an aggressive testimonial or email sequence.
Review:
Ad → Landing Page → Quiz/Form → Sales Page → Email/SMS → Booking/Checkout
8. Keep Regulatory Review Proportionate
Not every sentence requires the same level of review. The highest-risk statements are usually objective claims about diagnosis, treatment, prevention, safety, effectiveness, clinical performance, superiority, or regulatory status.
Build faster workflows around pre-approved claims rather than asking legal or regulatory teams to reinvent the review every launch.
FTC/FDA Marketing Audit
- Are objective health claims listed and supported?
- Have implied claims been reviewed?
- Are testimonials and endorsements evaluated as claims?
- Are material connections disclosed where required?
- Are FDA status terms accurate?
- Are device claims consistent with the applicable regulatory framework?
- Does the claims file exist before the campaign launches?
- Are old campaigns re-reviewed when products or evidence change?
Primary Sources
- FTC: Health Products Compliance Guidance
- FTC: Endorsements and Reviews
- FDA: Device Advice
- FDA: Device Registration and Listing
The Bottom Line
FTC and FDA compliance is not about making marketing timid. It is about making the commercial promise match the evidence, product status, and regulatory context.
